Cargando…
COVID-19 infection and vaccination in immunodeficiency
During the last 2 years and a half, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide, causing about 6 million deaths. Clinical manifestations are highly variable, ranging from entirely asymptomatic infection to multiorgan failure and death. The outcome in immunocompr...
Autores principales: | Piano Mortari, Eva, Pulvirenti, Federica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384801/ https://www.ncbi.nlm.nih.gov/pubmed/35972956 http://dx.doi.org/10.1093/cei/uxac080 |
Ejemplares similares
-
Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK
por: Shields, Adrian M, et al.
Publicado: (2022) -
Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig(®)) in the treatment of patients with primary immunodeficiencies
por: Kobayashi, Roger H, et al.
Publicado: (2022) -
British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy
por: Grigoriadou, S, et al.
Publicado: (2022) -
Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland
por: Santos, Galia M A, et al.
Publicado: (2019) -
Putative roles of solar UVA and UVB exposure and vitamin D supplementation in reducing risk of SARS-CoV-2 infection and COVID-19 severity
por: Grant, William B
Publicado: (2022)